Clinical trials: Hepatic Function
Protective Effect in TB-DIH, TB-DIH Means: Drug Induced Liver Function Abnormalities
The Protective Effect for Liver Organ in Patients With Anti-TB Drugs Using of Acetylcysteine (NAC)
Animal studies have shown that INH-RIF-induced oxidative injury can be prevented by supporting the cellular antioxidant defense mechanism by N-acetylcysteine (NAC).
- Trial name
- NCT02889757
- Testing
- Acteylcysteine
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- Far Eastern Memorial Hospital
Healthy
Dose-dependent Kinetics of Thiamin in Healthy Volunteers With and Without Functional OCT1 Hepatic Transporters
This study investigates the differences in thiamin (vitamin B1) kinetic parameters in two cohorts of healthy volunteers: Cohort 1) OCT1 wild type genotypes n = 12 Cohort 2) OCT1 deficient genotypes n = 12 Participants will be…
- Trial name
- THIAMO-1 (NCT06122701)
- Testing
- Thiamin p.o., Thiamin i.v.
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Mild Hepatic Imparement
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Participants With Mild Hepatic Impairment Compared With Participants With Normal Hepatic Function
This study is designed to assess the safety, tolerability and pharmacokinetics of ABI-6250 in participants with mild hepatic impairment compared with participants with normal hepatic function.
- Trial name
- NCT07850999
- Testing
- ABI-6250
- Where
- New Zealand
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Hepatocellular Carcinoma
A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function
This is an prospective, interventional, non-randomized multicenter phase II study to evaluate the safety, tolerability and efficacy of Cabozantinib as a second-line therapy (after one prior systemic therapy) in patients with…
- Trial name
- CaboCHILD (NCT04454762)
- Testing
- Cabozantinib
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Johannes Gutenberg University Mainz
Non-cystic Fibrosis Bronchiectasis (NCFBE)
Investigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Hepatic Impairment
The study is being conducted to compare the pharmacokinetics, safety of HSK31858 in subjects with mild, moderate, severe hepatic impairment and normal hepatic function.
- Trial name
- NCT07913009
- Testing
- HSK31858 tablets
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Diabetes Mellitus
Investigation of Pharmacokinetics and Safety of HRS-7535 in Subjects With Hepatic Impairment and Normal Hepatic Function
The study is being conducted to compare the pharmacokinetics and safety of HRS-7535 in subjects with mild to moderate hepatic impairment and normal hepatic function.
- Trial name
- NCT06961643
- Testing
- HRS-7535 Tables
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Hepatic Function Abnormal, Healthy Volunteers
A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)
This is a single-dose study to assess the effect of mild or moderate Hepatic Impairment (HI) on the Pharmacokinetics (PK) of rilzabrutinib as well as to evaluate the safety and tolerability of rilzabrutinib in subjects with HI.
- Trial name
- NCT06444204
- Testing
- Rilzabrutinib
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Principia Biopharma, a Sanofi Company
Postoperative Complications, Heart Diseases
Detection of Right Ventricular Dysfunction by Portal Vein Doppler After Cardiac Surgery
Right ventricular (RV) failure after cardiac surgery is associated with morbidity and mortality, but is hard to diagnose with conventional echocardiographic means.
- Conditions
- Postoperative Complications, Heart Diseases, Heart Failure, Heart Valve Diseases
- Trial name
- DVDDP (NCT04890860)
- Testing
- cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass
- Where
- France
- Volunteers
- 70 people
- Sponsor
- CMC Ambroise Paré
Hepatic Impairment
A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function
The primary objective is to assess the pharmacokinetics (PK) of apraglutide in subjects with hepatic impairment compared with matched control subjects with normal hepatic function following single subcutaneous (SC) dose…
- Trial name
- NCT05706623
- Testing
- Apraglutide
- Where
- 2 sites in Germany, Slovakia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- VectivBio AG
Hepatic Insufficiency & Healthy Subjects
Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function
This study is designed to evaluate the safety and pharmacokinetics of zanubrutinib in subjects with impaired liver function in comparison with healthy subjects
- Trial name
- NCT03465059
- Testing
- Zanubrutinib
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- BeiGene
Diabetes, Diabetes Mellitus, Type 2
Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
This trial is conducted in Europe. The aim of this trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), safety and tolerability after a single injection of semaglutide in subjects with mild…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Hepatic Impaired
- Trial name
- NCT02210871
- Testing
- semaglutide
- Where
- 4 sites in Poland, Slovakia
- Volunteers
- 44 people
- Sponsor
- Novo Nordisk A/S
Hepatic Impairment
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine
The primary purpose of this study is to assess the effect of hepatic impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe hepatic…
- Trial name
- NCT05935033
- Testing
- Emraclidine
- Where
- 3 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- AbbVie
Sever Aplastic Anaemia
A Trial of Hetrombopag in Healthy and Hepatic Impairment Subjects
This is a single-dose, open-label, phase I clinical study evaluating the PK of hetrombopag in subjects with mild hepatic impairment (Child-Pugh Class A), subjects with moderate hepatic impairment (Child-Pugh Class B), as well as…
- Trial name
- NCT05088642
- Testing
- Hetrombopag Olamine Tablet
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Liver Cirrhosis, Liver Failure
Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With "Acute-on-chronic Liver Failure"
The purpose of this study is to evaluate the effects on plasma exchange with 5% albumin on albumin functional capacity, cardiocirculatory, renal and cerebral function in cirrhotic patients with "acute-on-chronic liver failure".
- Trial name
- NCT01201720
- Testing
- Plasma exchange with albumin
- Where
- Spain
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Instituto Grifols, S.A.
Hepatic Impairment
Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function
This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic (PK) profiles of Chiglitazar following administration of a single oral dose in subjects with varying degrees of hepatic impairment…
- Trial name
- NCT05515445
- Testing
- Chiglitazar
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
Long QT Syndrome
Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function
The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of oral eleclazine and its metabolite, GS-623134, in participants with normal and impaired hepatic function.
- Trial name
- NCT02412098
- Testing
- Eleclazine
- Where
- 7 sites in United States, Germany and 2 more
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Postoperative Complications, Heart Failure
Association Between Portal Flow Pulsatility and Right Ventricular Dysfunction in the Postoperative Period of Cardiac Surgery
Right ventricular dysfunction (RVD) after cardiac surgery is associated with ischemia and myocardial injury. While echocardiographic measures like Tricuspid Annular Plane Systolic Excursion (TAPSE) are frequently used to assess…
- Trial name
- LIFESAVE (NCT06777355)
- Testing
- Transthoracic and Transesophageal echography within 24 hours post cardiac surgery
- Where
- France
- Volunteers
- 32 people
- Sponsor
- CMC Ambroise Paré
Liver and Biliary Tract Disorders in Duration of Pregnancy, Other End-stage Liver Diseases in Children
Prediction of Early Recovery of Liver Function After LDLT in Children: An Ambispective Cohort Study
The investigators included children with living donor liver transplantation (LDLT) from January 1, 2018 to July 31, 2022 as a retrospective cohort, and the group from August 1, 2022 to June 30, 2023 as a prospective cohort.
- Trial name
- NCT06045949
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Huiwu Xing
Liver Transplantation, Ischaemia Reperfusion Injury
Effect of Discarding Initial Reperfusion Blood on Hemodynamics, Liver Function, and 30-Day Outcomes in Liver Transplantation
Hepatic reperfusion during liver transplantation remains a critical phase associated with significant hemodynamic and systemic disturbances, despite advances in surgical and anesthetic management.
- Conditions
- Liver Transplantation, Ischaemia Reperfusion Injury, Perioperative Complications
- Trial name
- NCT07631689
- Testing
- Reperfusion Blood Discard, Standard Liver Transplantation
- Volunteers
- 132 people
- Sponsor
- University of Sao Paulo General Hospital
Metabolism, Liver Function
Interaction Between Cannabidiol, Meal Ingestion, and Liver Function
According to a recent consumer poll, over 20 million Americans regularly use cannabidiol (CBD). Moreover, 64 million Americans (over 25% of the population) report trying CBD at least once within the previous 2 years.
- Conditions
- Metabolism, Liver Function, Pharmacokinetics
- Trial name
- NCT04971837
- Testing
- Cannabidiol (CBD) powder formulation, Cannabidiol (CBD) Oil based tincture formulation, Cannabidiol (CBD) Gum Arabic, maltodextrin base formulation
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Colorado State University